Professor
National University of Singapore
Singapore, Singapore
Dr. Manjunatha Kini (PhD) is a professor in the Department of Biological Sciences, National University of Singapore (NUS). He holds a Joint Professor position in the Department of Pharmacology, Yong Loo Lin School of Medicine, NUS; Adjunct Senior Principal Investigator, Singapore Eye Research Institute, Singapore; and an Affiliate Professor in the Department of Biochemistry and Molecular Biology at the Virginia Commonwealth University, Richmond, Virginia, USA. He conducts basic and applied research on snake venoms and saliva of blood-feeding animals. He is an established world leader in the field of toxins as well as in thrombosis and hemostasis. His main research focus is "From Toxins to Therapeutics", where he identifies novel bioactive proteins from venoms or saliva, determines their modes of action, and designs potential drug-leads based on their structure. He published 218 original articles, 55 reviews and 19 book chapters, and filed 56 patent applications (33 issued). He edited two monographs “Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism” (1997, John Wiley, England) and “Toxins and Hemostasis: From Bench to Bedside” (2010, Springer, The Netherlands). He edited eight special issues for various journals. He was the Editor-in-Chief of Toxin Reviews for 10 years and is now the Editor Emeritus. He serves on the editorial boards of several international journals. He regularly reviews manuscripts, grant applications for several funding agencies in the world and evaluates recruitment, promotion and tenure documents for various research Institutes and research-intensive Universities globally. He has given over 140 Plenary/Keynote/Invited talks in International Conferences and over 220 seminars in Universities, Research institutes and Industries. He was the Chairman/Co-chairman of a subcommittee of the SSC of ISTH (1998-2016). He was a Council member (12 years), President-Elect (2015-2019) and President (2019-2020) of the International Society on Toxinology. He was the Vice President, International Proteolysis Society for two terms (2015-2019).
SOA 12.3 - Variegin, a Potent Direct Thrombin Inhibitor From Tick Saliva
Monday, June 26, 2023
08:50 – 09:15 ET